VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vir Biotechnology (VIR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong analyst ratings, positive clinical trial results, and promising collaboration with Astellas Pharma outweigh the short-term insider and hedge fund selling trends. The technical indicators are bullish, and the stock has solid growth potential in the oncology and hepatitis D markets.
The technical indicators for VIR are bullish. The MACD histogram is positive and expanding, the RSI is neutral at 71.186, and the moving averages (SMA_5 > SMA_20 > SMA_200) confirm an upward trend. The stock is trading near its resistance level (R1: 10.371), with potential for further upside.
Positive Phase 1 trial results for VIR-5500 in prostate cancer patients.
Co-development agreement with Astellas Pharma, securing $240 million in cash and a $75 million equity investment.
Analysts have consistently raised price targets, with a consensus view of strong growth potential.
Revenue increased by 417.78% YoY in Q4 2025.
Insider selling by the CEO and hedge fund selling trends.
Net income and EPS declined significantly YoY in Q4
No recent congress trading data to indicate political interest.
In Q4 2025, Vir Biotechnology's revenue increased by 417.78% YoY to $64.07 million, demonstrating strong top-line growth. However, net income dropped by 58.96% YoY to -$42.92 million, and EPS declined by 59.21% YoY to -0.31, indicating challenges in profitability. Gross margin improved to 99.96%, up 5.81% YoY, showcasing operational efficiency.
Analysts are highly optimistic about VIR, with multiple firms raising price targets significantly. H.C. Wainwright, BofA, Evercore ISI, Needham, Barclays, Raymond James, and Morgan Stanley have all increased their price targets, citing positive clinical trial data, strong partnerships, and growth potential in oncology and hepatitis D markets. The consensus is a strong buy with price targets ranging from $17 to $30.
